STAAR SURGICAL CO (STAA) Form 8-K — Sep 9, 2026
STAAR Surgical appointed David Bailey as Chief Commercial Officer effective September 8, 2026, marking the return of the company's former President and CEO (2001-2008) to its executive committee reporting to current CEO Warren Foust. Bailey's offer letter provides a CHF 462,825 (approximately $575,000) base salary, a 60% target bonus, an initial $850,000 RSU grant vesting over three years, and a prorated 2026 long-term incentive award valued at $1.4 million split evenly between stock options and RSUs.
Key figures
- Base Salary
- CHF 462,825 (approximately $575,000), prorated for 2026
- Target Bonus
- 60% of base salary for fiscal 2026, prorated
- Lti2026 Award
- $1,400,000, prorated, 50% stock options / 50% RSUs
- Icls Sold To Date
- more than 4 million in over 85 countries
- Fda Approval Of ICL
- 2005
- Initial Equity Grant
- $850,000 in RSUs vesting over three years (1/3 annually)
- Icl Revenue Growth Since
- more than tenfold
- International Revenue Share2011
- 74% of global total
- Icl Revenue At End Of Bailey Tenure2011
- approximately $32 million
- Capital Raised During Bailey Prior Tenure
- more than $60 million
Price after filing
Close on the filing date to close N calendar days later (from $23.62). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.